FTC Sues Golden Sunrise Nutraceutical For Marketing COVID-19 Treatment Plan
The Federal Trade Commission has charged a California-based company with deceptively advertising a $23,000 treatment plan by saying it is scientifically proven to treat COVID-19. The FTC’s complaint claims Golden Sunrise began marketing its Emergency D-Virus plan as a COVID-19 treatment in March of this year.
The company used billboards, websites, and social media to falsely claim that its supplements ImunStem, Aktiffvate, and AnterFeerons were “uniquely qualified to treat and modify the course of the Coronavirus epidemic in China and other countries”. It also claimed that users could expect the viral symptoms to disappear within two to four days.
In April of 2020, the FTC sent Golden Sunrise a letter warning the company to immediately remove all advertising claims that its products could prevent, treat, or cure COVID-19. Nevertheless, Golden Sunrise continues marketing ts products as a COVID-19 treatment.
Furthermore, the defendants have promoted and sold a variety of dietary supplements as treatments for Parkinson’s disease and cancer. Some of the products from Golden Sunrise cost as much as $170,000 to $200,000. In actuality, the products are comprised mainly of various herbs and spices. As for the health claims, they are unsubstantiated.
The FTC also accuses Golden Sunrise of falsely claiming their products and treatments have been reviewed and accepted by the FDA. The FTC received assistance from the Better Business Bureau Serving Central California & Inland Empire Counties with the investigation. As of today, all products have been removed from Golden Sunrise’s website.